RxDoctor Payments Data

Christopher Steidle, MD

Urology · Corbin, KYNPI 1295709871

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,393 of the $4,423 with a category attached, or 76.7%. 38 manufacturers reported payments, led by Axonics, Inc. at 24.7% of the total. Reporting peaked in 2021 at $1,793 and has fallen 79.5% since, to $367 in 2025.

$4,423in general payments, 2019–2025

Across 182 payments — averaging $24.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$692
  • Astellas Pharma US Inc$513
  • AbbVie$191
  • Sumitomo Pharma America, Inc.$166
  • Caldera Medical, Inc$160
  • plus $2K from 32 others

What the payments were for

  • Travel & lodging$72216%
  • Food & beverage$3,39377%
  • Education$2355%
  • Gifts$561%
  • Entertainment$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,423 in reported general payments places this provider in the 65th percentile of 139 urology providers in Kentucky.

See all urology providers in Kentucky

Medicare billing

Part B allowed, 2024
$179,288
Medicare patients
605
Services billed
1,790

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron66$41,752
Testosterone Cypionate362$28,174
MyrbetriqMirabegron31$22,891
Tamsulosin Hcl833$6,582
Finasteride591$5,431
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst154$4,987
Testosterone11$3,405
Bicalutamide80$1,855
Trimethoprim23$1,561
Solifenacin Succinate37$1,557
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip79$894
Ondansetron Hcl21$869
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim140$722
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen284$691
Anastrozole206$560

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$166$41,75266 claims
Astellas Pharma US IncMyrbetriq$513$22,89131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 139 urology providers in Kentucky.

Other urology in Corbin

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →